Naronapride

DB05542

small molecule investigational

Deskripsi

Struktur Molekul 2D

Berat 537.1
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

677 Data
Buprenorphine Naronapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Hydrocodone Naronapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Magnesium sulfate The therapeutic efficacy of Naronapride can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Naronapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Naronapride may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Mirtazapine Naronapride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Orphenadrine Naronapride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Naronapride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Pramipexole Naronapride may increase the sedative activities of Pramipexole.
Ropinirole Naronapride may increase the sedative activities of Ropinirole.
Rotigotine Naronapride may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Naronapride.
Sodium oxybate Naronapride may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Naronapride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Thalidomide Naronapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Naronapride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Naronapride.
Dicoumarol The risk or severity of adverse effects can be increased when Naronapride is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Naronapride is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Naronapride is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Naronapride is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Naronapride is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Naronapride is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Naronapride is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Naronapride is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Naronapride is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Naronapride is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Naronapride is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Naronapride is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Naronapride is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Naronapride is combined with (S)-Warfarin.
Ethanol Naronapride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Naronapride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Fluvoxamine The risk or severity of adverse effects can be increased when Naronapride is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Naronapride is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Naronapride is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Naronapride is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Naronapride is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Naronapride is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Naronapride is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Naronapride is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Naronapride is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Naronapride is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Naronapride is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Naronapride is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Naronapride is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Naronapride is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Naronapride is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Naronapride is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Naronapride is combined with Alaproclate.
Zopiclone The risk or severity of adverse effects can be increased when Naronapride is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Naronapride.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Naronapride.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Naronapride.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Naronapride.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Naronapride.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Naronapride.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Naronapride.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Naronapride.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Naronapride.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Naronapride.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Naronapride.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Naronapride.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Naronapride.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Naronapride.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Naronapride.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Naronapride.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Naronapride.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Naronapride.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Naronapride.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Naronapride.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Naronapride.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Naronapride.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Naronapride.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Naronapride.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Naronapride.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Naronapride.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Naronapride.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Naronapride.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Naronapride.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Naronapride.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Naronapride.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Naronapride.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Naronapride.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Naronapride.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Naronapride.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Naronapride.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Naronapride.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Naronapride.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Naronapride.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Naronapride.

Target Protein

5-hydroxytryptamine receptor 4 HTR4

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17187586
    Camilleri M, Vazquez-Roque MI, Burton D, Ford T, McKinzie S, Zinsmeister AR, Druzgala P: Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil. 2007 Jan;19(1):30-8.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul